Critically, CatB inhibition—through genetic ablation or small-molecule inhibitors—significantly impairs disease progression and severity, establishing it as a high-value therapeutic target, including in cancer and acute pancreatitis [1,2,3,4]. Here, TYRP1 is linked to cancer.